…
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Addex Therapeutics is a clinical-stage biopharmaceutical company developing allosteric modulators of metabotropic glutamate receptors for central nervous system disorders. Its long-term growth drivers include clinical advancement of differentiated mGluR candidates, potential licensing or partnerships, and unmet needs in neurodegenerative and psychiatric diseases. Investors may find the company attractive for its novel mechanism that could offer selective targeting and for value creation tied to clinical milestones.
Major risks include clinical trial failure and regulatory setbacks, frequent need for external financing leading to dilution, and limited commercial track record and market liquidity.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -4.91M | -2.50M | -20.80M | -15.35M | -12.86M |
| Net income | 7.06M | -10.56M | -21.07M | -15.41M | -12.93M |
| Selling general administrative | 1.68M | 2.03M | 7.30M | 5.14M | 5.15M |
| Selling and marketing expenses | - | 2.21M | - | - | - |
| Gross profit | 0.40M | 1.61M | 1.42M | 2.92M | 3.61M |
| Reconciled depreciation | 0.26M | 0.31M | 0.32M | 0.35M | 0.38M |
| Ebit | -4.91M | -2.50M | -20.52M | -15.51M | -12.24M |
| Ebitda | -4.65M | -2.19M | -20.17M | -15.15M | -11.83M |
| Depreciation and amortization | 0.26M | 0.31M | 0.35M | 0.35M | 0.41M |
| Operating income | -2.76M | -2.24M | -20.52M | -15.51M | -12.24M |
| Other operating expenses | 3.16M | 3.86M | 21.94M | 18.42M | 15.86M |
| Interest expense | 0.00M | 0.02M | 0.05M | 0.06M | 0.07M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.01M | 0.06M | 0.03M | 0.01M | 0.04M |
| Net interest income | 0.01M | 0.04M | -0.02M | -0.06M | -0.03M |
| Income tax expense | - | 0.02M | 0.26M | 0.06M | 0.07M |
| Total revenue | 0.40M | 1.61M | 1.42M | 2.92M | 3.61M |
| Total operating expenses | 3.16M | 3.86M | 21.94M | 18.42M | 15.86M |
| Cost of revenue | 0.85M | 6.94M | - | - | - |
| Total other income expense net | -2.15M | -0.26M | -0.28M | 0.15M | -0.62M |
| Net income from continuing ops | -4.91M | -10.56M | -20.80M | -15.35M | -12.86M |
| Net income applicable to common shares | - | - | -20.80M | -15.35M | -12.86M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 10.68M | 4.64M | 8.28M | 22.54M | 20.18M |
| Other current assets | 0.18M | 0.22M | 871.88M | 1.12M | 0.66M |
| Total liab | 1.00M | 3.50M | 3.37M | 5.61M | 5.57M |
| Total stockholder equity | 9.68M | 1.15M | 4.91M | 16.93M | 14.61M |
| Other current liab | 0.52M | 1.40M | 1.72M | 2.06M | 1.51M |
| Common stock | 1.84M | 1.84M | 1.15M | 49.27M | 32.85M |
| Capital stock | 1.84M | 1.84M | 1.15M | 49.27M | 32.85M |
| Retained earnings | -353.36M | -360.42M | -349.86M | -329.06M | -313.71M |
| Other liab | - | - | - | 1.28M | 1.69M |
| Other assets | - | - | 0.05M | 0.06M | 0.06M |
| Cash | 3.34M | 3.87M | 6.96M | 20.48M | 18.70M |
| Total current liabilities | 0.80M | 2.89M | 3.28M | 4.13M | 3.62M |
| Current deferred revenue | - | 0.23M | - | - | 0.82M |
| Net debt | -3.30M | -3.52M | -6.58M | -20.00M | -18.13M |
| Short term debt | 0.01M | 0.27M | 0.29M | 0.29M | 0.31M |
| Short long term debt total | 0.04M | 0.34M | 0.37M | 0.48M | 0.57M |
| Other stockholder equity | 330.13M | 329.91M | 327.85M | 272.28M | 286.89M |
| Property plant equipment | - | - | 0.40M | 0.54M | 0.63M |
| Total current assets | 3.54M | 4.23M | 7.83M | 21.94M | 19.49M |
| Long term investments | 7.09M | - | - | - | - |
| Net tangible assets | - | - | 4.91M | 16.93M | 14.61M |
| Short term investments | 0.01M | 0.00M | 0.00M | 0.02M | 0.06M |
| Net receivables | 0.02M | 0.15M | 0.60M | 0.32M | 0.07M |
| Inventory | - | - | -871.60M | - | - |
| Accounts payable | 0.25M | 0.98M | 1.28M | 1.79M | 0.98M |
| Accumulated other comprehensive income | 31.06M | 29.81M | 25.77M | 24.44M | 8.58M |
| Common stock total equity | - | - | - | - | 32.85M |
| Non currrent assets other | 0.01M | 0.05M | 0.05M | 0.06M | 0.06M |
| Non current assets total | 7.14M | 0.41M | 0.45M | 0.60M | 0.69M |
| Capital lease obligations | 0.04M | 0.34M | 0.37M | 0.48M | 0.57M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | 4.65M | -0.01M | 0.00M | 0.00M | -0.06M |
| Change to liabilities | - | - | -0.43M | 0.06M | -2.04M |
| Total cashflows from investing activities | 4.65M | -0.01M | 0.00M | -0.03M | -0.06M |
| Net borrowings | -0.07M | -0.28M | -0.29M | -0.31M | -0.37M |
| Total cash from financing activities | 0.10M | 5.26M | 3.10M | 16.40M | 0.05M |
| Change to operating activities | - | - | 0.86M | -0.57M | 0.17M |
| Net income | 7.06M | -10.56M | -20.80M | -15.35M | -12.86M |
| Change in cash | -0.52M | -3.09M | -13.53M | 1.79M | -12.84M |
| Begin period cash flow | 3.87M | 6.96M | 20.48M | 18.70M | 31.54M |
| End period cash flow | 3.34M | 3.87M | 6.96M | 20.48M | 18.70M |
| Total cash from operating activities | -5.37M | -7.99M | -16.44M | -14.71M | -12.18M |
| Issuance of capital stock | 0.24M | 2.35M | 1.68M | 13.96M | 0.72M |
| Depreciation | 0.26M | 0.31M | 0.32M | 0.35M | 0.38M |
| Other cashflows from investing activities | 5.12M | - | - | - | - |
| Dividends paid | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | - | 0.61M | - | - | - |
| Change to account receivables | 0.13M | 0.31M | -0.25M | -0.10M | 0.05M |
| Sale purchase of stock | -0.00M | -0.05M | - | - | - |
| Other cashflows from financing activities | -0.06M | 3.20M | 1.71M | 2.75M | -0.31M |
| Change to netincome | - | - | 3.89M | 1.06M | 2.12M |
| Capital expenditures | 0.00M | 0.01M | 0.00M | 0.03M | 0.06M |
| Change in working capital | -1.23M | 0.21M | 0.16M | -0.76M | -1.82M |
| Stock based compensation | - | 1.79M | 3.68M | 1.18M | 1.18M |
| Other non cash items | -11.46M | 0.25M | 0.20M | 0.03M | 0.97M |
| Free cash flow | -5.37M | -8.00M | -16.44M | -14.74M | -12.24M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ADXN Addex Therapeutics Ltd |
0.07 2.06% |
3.47 | - | - | 54.63 | 1.12 | 136.36 | -0.76 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
| Name | Title | Year Born |
|---|---|---|
| Mr. Timothy Mark Dyer | Co-Founder, CEO & Director | 1968 |
| Dr. Roger G. Mills M.D. | Chief Medical Officer & Director | 1957 |
| Mr. Lénaic Teyssédou | Head of Fin. | 1986 |
| Dr. Jean-Philippe Rocher Ph.D. | Head of Discovery - Chemistry | 1959 |
| Dr. Robert Lutjens | Head of Discovery - Biology | 1968 |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science | 1968 |
| Dr. Werner Henrichi Ph.D. | Consultant | 1943 |
| Mr. Lénaic Teyssédou | Head of Finance | 1986 |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.